461 related articles for article (PubMed ID: 25773177)
21. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D Deficiency Increases Lipogenesis and Reduces Beta-Oxidation in the Liver of Diet-Induced Obese Mice.
Borges CC; Salles AF; Bringhenti I; Mandarim-DE-Lacerda CA; Aguila MB
J Nutr Sci Vitaminol (Tokyo); 2018; 64(2):106-115. PubMed ID: 29710028
[TBL] [Abstract][Full Text] [Related]
23. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
25. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
[TBL] [Abstract][Full Text] [Related]
26. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.
Perfield JW; Ortinau LC; Pickering RT; Ruebel ML; Meers GM; Rector RS
J Obes; 2013; 2013():296537. PubMed ID: 23401753
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis.
Misra P; Reddy JK
Biochimie; 2014 Mar; 98():63-74. PubMed ID: 24291192
[TBL] [Abstract][Full Text] [Related]
28. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
[TBL] [Abstract][Full Text] [Related]
29. Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis.
Monsénégo J; Mansouri A; Akkaoui M; Lenoir V; Esnous C; Fauveau V; Tavernier V; Girard J; Prip-Buus C
J Hepatol; 2012 Mar; 56(3):632-9. PubMed ID: 22037024
[TBL] [Abstract][Full Text] [Related]
30. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
[No Abstract] [Full Text] [Related]
31. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
[TBL] [Abstract][Full Text] [Related]
32. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
33. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
[TBL] [Abstract][Full Text] [Related]
34. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
[TBL] [Abstract][Full Text] [Related]
35. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice.
Zhao L; Zhong S; Qu H; Xie Y; Cao Z; Li Q; Yang P; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
Sci Rep; 2015 May; 5():10222. PubMed ID: 25974206
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse.
Brix AE; Elgavish A; Nagy TR; Gower BA; Rhead WJ; Wood PA
Mol Genet Metab; 2002 Mar; 75(3):219-26. PubMed ID: 11914033
[TBL] [Abstract][Full Text] [Related]
37. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643.
Edvardsson U; Alexandersson M; Brockenhuus von Löwenhielm H; Nyström AC; Ljung B; Nilsson F; Dahllöf B
Electrophoresis; 1999; 20(4-5):935-42. PubMed ID: 10344269
[TBL] [Abstract][Full Text] [Related]
38. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
Goetzman ES; Tian L; Wood PA
Mol Genet Metab; 2005 Jan; 84(1):39-47. PubMed ID: 15639194
[TBL] [Abstract][Full Text] [Related]
39. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPARα activation.
Shin SS; Yoon M
Pharm Biol; 2012 Oct; 50(10):1261-8. PubMed ID: 22870903
[TBL] [Abstract][Full Text] [Related]
40. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
